| Autor: |
Groen K; Department of Hematology, Amsterdam UMC, Vrije Universiteit, the Netherlands.; Cancer Center Amsterdam, Treatment and Quality of Life, the Netherlands., Schjesvold FH; Department of Hematology, Oslo Myeloma Center, Oslo University Hospital, Norway.; KG Jebsen Center for B Cell Malignancies, University of Oslo, Norway., van der Holt B; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands., Seefat MR; Department of Hematology, Amsterdam UMC, Vrije Universiteit, the Netherlands.; Cancer Center Amsterdam, Treatment and Quality of Life, the Netherlands., Hansson M; Department of Hematology, Skåne University Hospital Lund, Sweden., Leys MBL; Department of Internal Medicine, Maasstad Hospital, Rotterdam, the Netherlands., Regelink JC; Department of Internal Medicine, Meander Medical Centre, Amersfoort, the Netherlands., Waage A; Institute of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway., Szatkowski D; Department of Oncology and Hematology, Førde Central Hospital, Norway., Axelsson P; Department of Internal Medicine, Helsingborg Hospital, Sweden., Hieu Do T; Haematology Department H 60, Roskilde Sjaelland University, Denmark., Svirskaite A; Department of Hematology, Aalborg University Hospital, Denmark., van der Spek E; Department of Internal Medicine, Rijnstate Hospital, Arnhem, the Netherlands., Haukas E; Department for Blood and Cancer Diseases, Stavanger University Hospital, Norway., Knut-Bojanowska D; Institute of Heamatology, Uddevalla Hospital, Sweden., Ypma PF; Department of Hematology, Haga Hospital, The Hague, the Netherlands., Blimark CH; Hematology Department, Sahlgrenska University Hospital, Gothenburg, Sweden., Mellqvist UH; Department of Internal Medicine, Sodra Alvsborgs Sjukhus, Boras, Sweden., van de Donk NWCJ; Department of Hematology, Amsterdam UMC, Vrije Universiteit, the Netherlands.; Cancer Center Amsterdam, Treatment and Quality of Life, the Netherlands., Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Klostergaard A; Department of Hematology, Aarhus University Hospital, Denmark., Vangsted AJ; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Abildgaard N; Department of Hematology, Hematology Research Unit and Academy of Geriatric Research, Odense University Hospital and University of Southern Denmark, Denmark., Zweegman S; Department of Hematology, Amsterdam UMC, Vrije Universiteit, the Netherlands.; Cancer Center Amsterdam, Treatment and Quality of Life, the Netherlands. |
| Abstrakt: |
Competing Interests: FHS: Grants or contracts from Celgene, Janssen, Oncopeptides, Sanofi, GSK Targovax. Payments or honoraria for lectures/presentations/speakers bureus/article writing or educational events: Amgen, BMS, Takeda, Abbvie, Janssen, Novartis, SkyliteDX, Oncopeptides, Sanofi, Pfizer, Daiki-Sankyo, GSK. Participation on a Data Safety Monitoring Board or Advisory Board: Abbvie, GSK, Celgene, Takeda, Janssen, Oncopeptides, Sanofi, BMS. MH: Royalties of payments for lectures: Janssen, BMS, Pfizer. EvdS: Royalties for lectures Janssen. PFY: Royalties of payments for lectures/article preparations/etc: Janssen and Amgen: participation in a company sponsored speakers’ bureau. UHM: Employment/Consultation: Advisory boards: Amgen, Sanofi, Pfizer. Royalties of payments for lectures/article preparations/etc: Lecture honoraria: Amgen, Janssen, BMS, Sanofi, GSK. NWCJvdD: Research support from Janssen Pharmaceuticals, AMGEN, Celgene, Novartis, Cellectis and BMS, and serves in advisory boards for Janssen Pharmaceuticals, AMGEN, Celgene, BMS, Takeda, Roche, Novartis, Bayer, Adaptive, and Servier. PS: Consulting or Advisory Role: Celgene, Janssen, Amgen, Karyopharm Therapeutics, CARsgen Therapeutics, Pfizer. Research Funding: Janssen, Amgen, BMS/Celgene. NA: Research grant, honorarium and advisory board, Takeda. SZ: Consulting or Advisory Role: Janssen-Cilag, Takeda, Celgene/Bristol Myers Squibb, Sanofi, Oncopeptides (no personal funding). Research Funding: Janssen, Takeda. All the other authors have no conflicts of interest to disclose. |
Plný text